


BISPECIFIC ANTIBODY DRUG ELISA

FOR DRUG INTERACTION,
PHARMACO-KINETIC STUDIES
AND DEVELOPMENT OF
THERAPEUTIC DRUGS

BsAbs have been shown to be clinically superior to monoclonal antibodies in their specificity and have a wide range of therapeutic applications under tumor and other diseases. Their clear advantage is the enhanced specificity, target-ability and reduced off-target toxicity they allow for.

- All kits offer quantitative results for both serum and plasma samples. Can be customised for other matrices.
- Developed using two anti-idiotypic monoclonal antibodies for each binding target in a sandwich format
- Lot to Lot consistency

**40 + DRUG
TARGETS IN A
STANDARD 96 WELL
FORMAT**



Kit includes Sample Diluent and other necessary reagents for running the ELISA, in a break-apart 96 well format with proprietary solutions.

✓ SPECIFIC
ANTIBODIES

✓ REPRODUCIBLE
RESULTS

✓ VALIDATED AS
PER US FDA

✓ COMPETITIVE
PRICING

WORLD'S ONLY ELISA FOR BISPECIFIC ANTIBODY DRUGS

Currently, there are seven bispecific antibodies approved by FDA and EMA, more than 180 BsAbs are in preclinical development, and over 50 BsAbs have been investigated in clinical trials.

From the concept phase to clinical trials, many companies around the world are accelerating their research and development processes of these drugs, especially CD3-targeting bsAbs. This means that quality control of bsAb drugs becomes even more critical, especially as a novel immunotherapeutic.

Krishgen offers a range of ELISA to quantify bispecific antibody drug levels accurately and quickly in serum and plasma samples.

| | |
|---------|-----------------------------------|
| KBI1751 | KRIBIOLISA™ Acapatamab ELISA |
| KBI1752 | KRIBIOLISA™ Alnuctamab ELISA |
| KBI1130 | KRIBIOLISA™ Amivantamab ELISA |
| KBI1197 | KRIBIOLISA™ Blinatumomab ELISA |
| KBI1222 | KRIBIOLISA™ Catumaxomab ELISA |
| KBI1753 | KRIBIOLISA™ Cevostamab ELISA |
| KBI1231 | KRIBIOLISA™ Cibisatamab ELISA |
| KBI1754 | KRIBIOLISA™ Cinrebausp alfa ELISA |
| KBI1755 | KRIBIOLISA™ Duvortuxizumab ELISA |
| KBI1756 | KRIBIOLISA™ Elranatamab ELISA |
| KBI1757 | KRIBIOLISA™ Eluvixtamab ELISA |
| KBI1758 | KRIBIOLISA™ Emerfetamab ELISA |
| KBI1297 | KRIBIOLISA™ Emicizumab ELISA |
| KBI1310 | KRIBIOLISA™ Epcoritamab ELISA |
| KBI1317 | KRIBIOLISA™ Ertumaxomab ELISA |
| KBI1759 | KRIBIOLISA™ Etevritamab ELISA |
| KBI1326 | KRIBIOLISA™ Faricimab ELISA |
| KBI1337 | KRIBIOLISA™ Flotetuzumab ELISA |
| KBI1366 | KRIBIOLISA™ Glofitamab ELISA |
| KBI1760 | KRIBIOLISA™ Gresonitamab ELISA |
| KBI1761 | KRIBIOLISA™ Ivicentamab ELISA |
| KBI1478 | KRIBIOLISA™ Mosunetuzumab ELISA |

| | |
|---------|---------------------------------|
| KBI1492 | KRIBIOLISA™ Navicixizumab ELISA |
| KBI1762 | KRIBIOLISA™ Nivatrotamab ELISA |
| KBI1763 | KRIBIOLISA™ Obrindatamab ELISA |
| KBI1764 | KRIBIOLISA™ Odronextamab ELISA |
| KBI1765 | KRIBIOLISA™ Pacanalotamab ELISA |
| KBI1546 | KRIBIOLISA™ Pasotuxizumab ELISA |
| KBI1766 | KRIBIOLISA™ Pavurutamab ELISA |
| KBI1559 | KRIBIOLISA™ Plamotamab ELISA |
| KBI1766 | KRIBIOLISA™ Runimotamab ELISA |
| KBI1767 | KRIBIOLISA™ Solitomab ELISA |
| KBI1768 | KRIBIOLISA™ Talquetamab ELISA |
| KBI1769 | KRIBIOLISA™ Tarlatamab ELISA |
| KBI1667 | KRIBIOLISA™ Teclistamab ELISA |
| KBI1770 | KRIBIOLISA™ Tepoditamab ELISA |
| KBI1682 | KRIBIOLISA™ Tidutamab ELISA |
| KBI1771 | KRIBIOLISA™ Ubamatamab ELISA |
| KBI1772 | KRIBIOLISA™ Vepsitamab ELISA |
| KBI1773 | KRIBIOLISA™ Vibecotamab ELISA |
| KBI1774 | KRIBIOLISA™ Vixtimotamab ELISA |
| KBI1775 | KRIBIOLISA™ Voxalatamab ELISA |
| KBI1745 | KRIBIOLISA™ Zanidatamab ELISA |
| KBI1748 | KRIBIOLISA™ Zenocutuzumab ELISA |



Official distributor in Spain and Portugal